Aqueous biomarkers may help predict treatment response in neovascular age-related macular degeneration
Aqueous biomarkers could help identify patients with neovascular age-related macular degeneration (nvAMD) who may not require, or who may not benefit from, long-term antivascular endothelial growth factor (VEGF) therapy.